Education
About Us
Working with TipRanks
Follow Us
Otsuka Holdings Co Ltd (OTSKY)
OTHER OTC:OTSKY
Top Page
Otsuka Holdings Co
(OTC:OTSKY)
Select Model
Select Model
Rating:75Outperform
Price Target:
$39.00
▲(31.36% Upside)
Action:ReiteratedDate:02/18/26
The score is driven primarily by strong financial performance (revenue growth, profit rebound, improving free cash flow, and low leverage). Valuation is reasonable at a mid-teens P/E with a modest dividend yield. Offsetting these positives, technical indicators suggest the stock is extended/overbought (high RSI and Stoch), which raises near-term downside risk.
Positive Factors
Consistent revenue growth
Sustained top-line growth from ¥1.42T to ¥2.59T over 2020–2025 indicates durable market demand and successful product commercialization. Steady revenue expansion supports reinvestment in R&D and global commercialization, underpinning longer-term earnings power and strategic flexibility.
Improving free cash flow
Rising operating and free cash flow to ¥423B and ¥331B in 2025 demonstrates strengthening cash generation. Improved FCF enables capital allocation to R&D, M&A, dividends or debt reduction, reducing reliance on external financing and supporting sustainable investment in core pharmaceutical pipelines.
Conservative balance sheet
A conservatively leveraged balance sheet with rising equity (~¥3.04T) and manageable debt provides financial resilience. Low leverage preserves capacity to fund long-term R&D and acquisitions, weather cyclical pressures, and maintain liquidity for strategic opportunities without forcing distress-driven asset sales.
Negative Factors
Margin pressure/volatility
Profitability has rebounded, but margins remain below 2020 peaks, signaling structural pressures such as mix shifts, pricing or cost increases. Persistent margin variability can limit operating leverage benefits from revenue growth and constrain long-term free cash flow expansion if not addressed.
Higher total debt in 2025
A material jump in total debt in 2025 increases refinancing and interest risk even if leverage remains low. If debt funds one-time items or M&A rather than growth projects, higher gross debt could reduce financial flexibility and raise long-term funding costs during adverse macro or rate environments.
Moderate cash conversion
Operating cash conversion below 1 and FCF at ~49%–64% of net income suggests earnings are partly tied up in working capital or timing items. This reduces the immediate deployable cash from reported profits, which can constrain sustained financing of R&D, dividends, or debt repayments.
Otsuka Holdings Co (OTSKY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$35.03B
Dividend Yield1.48%
Average Volume (3M)4.89K
Price to Earnings (P/E)15.0
Beta (1Y)0.12
Revenue Growth7.51%
EPS Growth203.70%
CountryUS
Employees35,338
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)0.41
Shares Outstanding1,085,977,800
10 Day Avg. Volume2,307
30 Day Avg. Volume4,892
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)1.55
Price to Sales (P/S)1.82
P/FCF Ratio14.23
Enterprise Value/Market Cap146.28
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit2.87
Enterprise Value/Ebitda8.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.79
Revenue Forecast (FY)$16.10B
Otsuka Holdings Co Business Overview & Revenue Model
Company DescriptionOtsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine. In addition, the company offers soft drinks, food products, and wines; chemicals; clinical testing and medical equipment; cosmetics; warehousing and transport services; analysis and measurement equipment; pharmaceutical intermediates; vehicle headlight testers; synthetic resin molded products; paper products; artificial turf; ceramic boards, ceramic walls, reliefs, terracotta, OT ceramics, and ceramic portraits and sign boards; functional films; stable isotopes; software and services to enhance management of mental healthcare systems; potassium titanate; polyolefin foams; spring and mineral water; industrial chemicals; hydrazine; insecticide and toiletry products; and adhesive tapes. Further, it operates a hotel. Otsuka Holdings Co., Ltd. was founded in 1921 and is based in Tokyo, Japan.
How the Company Makes MoneyOtsuka Holdings generates revenue primarily through the sale of pharmaceutical products, which account for a significant portion of its income. The company markets a range of prescription drugs, with a strong focus on areas such as psychiatry, neurology, and oncology. Key revenue streams include the commercialization of patented drugs and ongoing sales of established products. Additionally, Otsuka diversifies its income through its nutraceutical segment, which includes health supplements and functional beverages. The company often engages in strategic partnerships and collaborations with other pharmaceutical firms, research institutions, and healthcare organizations to enhance its product offerings and expand market reach. This collaborative approach contributes to its earnings by enabling access to new technologies and markets, as well as sharing research and development costs.
Otsuka Holdings Co Earnings Call Summary
Earnings Call Date:Aug 01, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:May 08, 2026
Earnings Call Sentiment Positive
The earnings call presented a strong overall performance in both pharmaceutical and nutraceutical segments with significant revenue and profit growth, and positive strategic expansions such as the acquisition for drug discovery. However, there were challenges such as impairment losses and increased SG&A expenses.Q2-2024 Updates
Positive Updates
Significant Revenue and Profit Growth
Revenue increased by 17.0% to JPY 1,108.9 billion, and business profit grew by 37.8% to JPY 213.6 billion year-on-year, highlighting strong performance in pharmaceutical and nutraceutical segments.
Nutraceutical Business Expansion
The Nutraceutical business achieved over 20% growth, with revenue increasing in all three categories, notably For Women's Health at 56.9% and For Healthier Life at 25.5%.
Pharmaceutical Business Growth
Revenue in the pharmaceutical business increased by 17.9% year-on-year to JPY 766.7 billion, with significant contributions from products like REXULTI and LONSURF.
Upward Revision of Financial Forecast
The full-year revenue forecast was revised up by JPY 175 billion to JPY 2,315 billion, and business profit was revised up by JPY 60 billion to JPY 390 billion.
Acquisition for Drug Discovery
Announcement of the acquisition of a company in Boston for drug discovery technology, indicating strategic expansion.
Negative Updates
Impairment Loss Impact
Operating profit was impacted by an impairment loss on AVP-786, which led to strategic discontinuation of its development.
Decrease in Milestone Revenue
Upfront milestone and royalty revenue decreased to JPY 41.8 billion due to lower sales milestone income compared to the previous year.
Increase in SG&A Expenses
SG&A expenses increased due to higher promotion expenses, impacting overall cost management.
Company Guidance
During the Q2 2024 earnings call for 4578.T, significant financial growth was highlighted, with revenue increasing by 17.0% to JPY 1,108.9 billion and business profit rising by 37.8% to JPY 213.6 billion year-on-year, driven by strong performance in pharmaceutical and nutraceutical segments. Despite an impairment loss on AVP-786 affecting operating profit, net profit climbed by 5.1% due to finance income. The pharmaceutical business saw revenue increase by 17.9% to JPY 766.7 billion, bolstered by products like ABILIFY MAINTENA and JYNARQUE, while LONSURF achieved significant gains through colorectal cancer treatment guidelines endorsements. Nutraceuticals experienced over 20% growth, with revenue reaching JPY 271.8 billion, fueled by a 56.9% rise in the For Women's Health category. The company revised its full-year forecast, raising revenue expectations by JPY 175 billion to JPY 2,315 billion and business profit projections by JPY 60 billion to JPY 390 billion, aiming to maintain momentum through strategic investments and addressing social issues.Otsuka Holdings Co Financial Statement Overview
Summary
Strong overall fundamentals: consistent revenue growth through 2025, a meaningful profit rebound in 2024–2025, improving free cash flow, and a conservatively leveraged balance sheet. Key watch items are margin volatility versus 2020 levels and higher total debt in 2025 (though leverage remains low).Income Statement
Revenue has grown consistently from 2020 to 2025 (from ~¥1.42T to ~¥2.59T), with strong growth in 2023–2025. Profitability improved meaningfully versus 2023 (net income rose from ~¥122B in 2023 to ~¥343B in 2024 and ~¥381B in 2025), indicating better operating performance and/or mix. That said, margins were noticeably stronger in 2020 and have not fully returned to prior highs, pointing to some longer-term pressure/volatility in profitability despite the recent rebound.78
Positive
Balance Sheet
The balance sheet looks conservatively positioned: leverage is low based on the provided debt-to-equity levels (roughly 0.07–0.12 in 2020–2024), and equity has steadily increased (to ~¥3.04T in 2025) alongside a growing asset base (~¥4.20T in 2025). A watch item is that total debt rose in 2025 versus 2024 (from ~¥189B to ~¥307B), but overall leverage still appears very manageable given the size of equity.86
Very Positive
Cash Flow
Cash generation is solid and improving: operating cash flow increased over time (to ~¥423B in 2025) and free cash flow rose to ~¥331B in 2025, with positive free-cash-flow growth in recent years (notably 2023–2025). Cash flow conversion vs profits is moderate based on the provided metrics in 2022–2024 (free cash flow running at ~49%–64% of net income), and operating cash flow relative to net income is below 1 in those years, suggesting some earnings are tied up in working capital or other non-cash timing—still acceptable given the overall upward cash trend.80
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.59T | 2.33T | 2.02T | 1.74T | 1.50T |
| Gross Profit | 1.86T | 1.67T | 1.41T | 1.17T | 1.00T |
| EBITDA | 554.23B | 452.62B | 246.96B | 279.83B | 231.43B |
| Net Income | 380.76B | 343.12B | 121.62B | 133.91B | 125.46B |
Balance Sheet | |||||
| Total Assets | 4.20T | 3.74T | 3.36T | 3.10T | 2.82T |
| Cash, Cash Equivalents and Short-Term Investments | 535.01B | 458.08B | 529.40B | 489.12B | 430.76B |
| Total Debt | 307.25B | 189.38B | 214.19B | 194.16B | 212.45B |
| Total Liabilities | 1.10T | 961.09B | 924.93B | 840.17B | 775.73B |
| Stockholders Equity | 3.04T | 2.73T | 2.39T | 2.23T | 2.01T |
Cash Flow | |||||
| Free Cash Flow | 331.04B | 225.28B | 168.56B | 104.06B | 115.71B |
| Operating Cash Flow | 423.14B | 354.64B | 283.23B | 211.85B | 228.86B |
| Investing Cash Flow | -169.42B | -265.79B | -190.54B | -81.58B | -95.29B |
| Financing Cash Flow | -144.00B | -189.37B | -60.26B | -95.47B | -95.84B |
Otsuka Holdings Co Technical Analysis
Positive
29.69
Price Trends
30.43
Positive
29.07
Positive
27.18
Positive
Market Momentum
1.05
Positive
56.19
Neutral
32.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTSKY, the sentiment is Positive. The current price of 29.69 is below the 20-day moving average (MA) of 32.46, below the 50-day MA of 30.43, and above the 200-day MA of 27.18, indicating a bullish trend. The MACD of 1.05 indicates Positive momentum. The RSI at 56.19 is Neutral, neither overbought nor oversold. The STOCH value of 32.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OTSKY.
Otsuka Holdings Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $35.03B | 14.98 | 15.51% | 1.48% | 7.51% | 203.70% | |
74 Outperform | $186.25B | 21.97 | 40.49% | 2.52% | 2.76% | 6407.19% | |
71 Outperform | $126.95B | 18.03 | 40.53% | 4.84% | 1.26% | ― | |
69 Neutral | $115.34B | 20.23 | 6.76% | 4.58% | -9.32% | 120.62% | |
67 Neutral | $117.79B | 15.90 | 38.48% | 3.41% | 5.97% | 128.66% | |
64 Neutral | $27.60B | 21.36 | 7.39% | ― | 5.00% | -1.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
OTSKY
Otsuka Holdings Co
32.10
7.14
28.60%
BIIB
Biogen
184.02
41.37
29.00%
BMY
Bristol-Myers Squibb
61.22
4.64
8.20%
GILD
Gilead Sciences
147.83
36.21
32.44%
GSK
GlaxoSmithKline
57.07
20.11
54.42%
SNY
Sanofi
46.47
-9.45
-16.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.